Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Aprea Therapeutics Inc

Healthcare US APRE

0.815USD
-0.013(1.57%)

Last update at 2026-06-24T17:46:00Z

Day Range

0.790.85
LowHigh

52 Week Range

0.552.22
LowHigh

Fundamentals

  • Previous Close 0.83
  • Market Cap11.23M
  • Volume36276
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-13.21212M
  • Revenue TTM0.29M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM -6.75728M
  • Diluted EPS TTM-1.93

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -12.59957M -12.95871M -14.28676M -112.66203M -37.12730M
Minority interest - - - - -
Net income -12.59957M -12.95871M -14.28676M -224.87539M -36.53658M
Selling general administrative 6.48M 6.46M 8.43M 20.97M 13.55M
Selling and marketing expenses - - 0.00705M - -
Gross profit 0.26M -7.86096M 0.58M - -
Reconciled depreciation 0.02M 0.02M -0.00032M 0.19M 0.27M
Ebit -13.25555M -14.31965M -14.28676M 38.18M -38.03543M
Ebitda -13.23384M -14.29734M -14.27971M 38.37M -37.76376M
Depreciation and amortization 0.02M 0.02M 0.00705M 0.19M 0.27M
Non operating income net other - - - - -
Operating income -13.23384M -14.31965M -15.47196M 38.18M -38.03543M
Other operating expenses 13.52M 15.82M 16.06M 37.37M 37.45M
Interest expense - - - 0.45M 0.00165M
Tax provision - - - - -
Interest income 0.65M 1.29M 1.22M 0.45M 0.00165M
Net interest income 0.65M 1.29M 1.16M 0.45M 0.00165M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.00000M 112.21M -0.59073M
Total revenue 0.29M 1.50M 0.58M 0.00000M 0.00000M
Total operating expenses 13.52M 6.46M 16.05M 37.37M 37.45M
Cost of revenue 0.02M 9.36M 0.00705M - -
Total other income expense net 0.63M 1.36M 1.19M -150.84219M 0.91M
Discontinued operations - - - - -
Net income from continuing ops -12.59957M -12.95871M -13.28564M -112.66203M -37.12730M
Net income applicable to common shares - - - -112.66203M -37.12730M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 15.93M 23.98M 22.65M 30.16M 56.82M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.96M 0.73M 0.91M 1.37M 3.51M
Total liab 3.49M 4.67M 4.39M 4.51M 7.32M
Total stockholder equity 13.17M 19.31M 18.26M 25.64M 49.51M
Deferred long term liab - - - - -
Other current liab 2.05M 2.01M 2.19M 2.36M 5.35M
Common stock 0.00819M 0.00548M 0.00374M 0.00265M 0.02M
Capital stock 0.00819M 0.00548M 0.00374M 0.00265M 0.02M
Retained earnings -333.64144M -321.04187M -308.08316M -293.79640M -181.13438M
Other liab - - - - -
Good will - - - - -
Other assets - - - - 0.03M
Cash 14.60M 22.85M 21.61M 28.79M 53.08M
Cash and equivalents - - - - -
Total current liabilities 2.76M 3.36M 4.39M 3.20M 7.32M
Current deferred revenue - - 0.53M - -
Net debt -14.59935M -22.84989M -21.60682M -28.78665M -52.88558M
Short term debt - - - - 0.19M
Short long term debt - - - - -
Short long term debt total - - - - 0.19M
Other stockholder equity 356.71M 350.97M 335.64M 328.75M 240.98M
Property plant equipment - - - 0.00232M 0.21M
Total current assets 15.56M 23.58M 22.52M 30.15M 56.58M
Long term investments - - - - -
Net tangible assets - - - 25.64M 49.51M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.71M 1.35M 1.67M 0.84M 1.77M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -10.63471M -10.62738M -10.61127M -10.62341M -10.35896M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.27M 0.28M 0.04M - 0.03M
Deferred long term asset charges - - - - -
Non current assets total 0.37M 0.40M 0.13M 0.00232M 0.24M
Capital lease obligations - - - 0.00000M 0.19M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.01548M -0.08594M 0.00000M 0.00000M
Change to liabilities - - - -0.85851M -2.73059M
Total cashflows from investing activities - -0.01548M -0.09309M - -
Net borrowings - - - - -
Total cash from financing activities 4.64M 14.82M 5.14M 0.68M 1.75M
Change to operating activities - - - -0.90007M -5.59631M
Net income -12.59957M -12.95871M -14.28676M -112.66203M -37.12730M
Change in cash -8.24952M 1.24M -7.13911M -24.28940M -35.94163M
Begin period cash flow 22.89M 21.65M 28.79M 53.08M 89.02M
End period cash flow 14.64M 22.89M 21.65M 28.79M 53.08M
Total cash from operating activities -12.89444M -13.55672M -12.17761M -25.01114M -37.68618M
Issuance of capital stock 5.05M 16.14M 5.89M 0.68M 1.54M
Depreciation 0.02M 0.02M 0.00705M 0.19M 0.27M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 4.64M -1.31846M -0.64893M -69.42419M 0.21M
Change to netincome - - - 89.22M 7.50M
Capital expenditures 0.00000M 0.02M 0.09M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.92910M -1.05540M 1.62M -1.75858M -8.32689M
Stock based compensation 0.48M 0.49M 0.44M 16.98M 7.81M
Other non cash items 0.13M -0.05436M 0.04M 72.24M -0.31740M
Free cash flow -12.89444M -13.57220M -12.27070M -25.01114M -37.68618M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
APRE
Aprea Therapeutics Inc		 -0.013 1.57% 0.81 - - 39.32 0.90 0.35
NVO
Novo Nordisk A/S		 0.03 0.05% 47.45 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.16 2.48% 48.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 8.43 1.80% 476.85 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 7.92 1.28% 625.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Aprea Therapeutics Inc

3805 Old Easton Road, Doylestown, PA, United States, 18902

Key Executives

Name Title Year Born
Mr. Christian S. Schade Chairman & CEO 1961
Dr. Oren Gilad Ph.D. Co-Founder, Pres & Director 1968
Mr. Scott M. Coiante Sr. VP, CFO & Sec. 1967
Dr. Gregory A. Korbel Ph.D. Sr. VP & COO 1976
Dr. Dansu Li Ph.D. Head of Technology NA
Dr. Lars B. Abrahmsen Ph.D. Sr. VP & Chief Scientific Officer 1957
Dr. Rifat Pamukcu M.D. Chief Medical Advisor & Director 1958
Mr. Hank Breslin Head of Medicinal Chemistry NA
Dr. Michel Afargan Ph.D. Head of Pharmacology Devel. NA
Ms. Andrea Epstein Controller NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.